Skip to main content
. 2021 Jul 17;14:3299–3306. doi: 10.2147/DMSO.S318255

Table 2.

Characteristics of Participants

All Tertile 1 Tertile 2 Tertile 3 P
1432 478 477 477
Sex (male, %) 829 (57.9) 257 (53.8) 273 (57.2) 299 (62.7) 0.019
Age (years) 61 (52, 68) 64 (56, 69) 62 (52, 67) 56 (49, 65) <0.001
Duration of diabetes (years) 9 (3, 14) 10 (5, 15) 9 (3, 15) 7 (2, 13) <0.001
History of hypertension, n(%) 663 (46.3) 223 (46.7) 212 (44.4) 228 (47.8) 0.573
SBP (mmHg) 132 (120, 145) 133 (120, 46) 132 (119, 142) 132 (121, 146) 0.294
DBP (mmHg) 78 (70, 86) 75 (67, 84) 76 (70, 85) 81 (72, 89) <0.001
BMI (kg/m2) 24.3 (22.3, 26.6) 23.4 (21.6, 25.4) 24.4 (22.4, 26.7) 25.2 (23.0, 27.5) <0.001
WC (cm) 89 (83, 96) 86 (80, 92) 90 (84, 96) 92 (86, 99) <0.001
FPG (mg/dL) 144 (117, 184) 115.2 (100.8, 136.8) 144.0 (122.4, 171.0) 183.6 (146.7, 237.6) <0.001
PBG (mmol/L) 12.3 (9.5, 16.1) 10.9 (8.3, 13.8) 12.1 (9.5, 15.7) 14.6 (11.4, 18.5) <0.001
HbA1C (%) 8.5 (7.1, 10.4) 7.4 (6.6, 9.4) 8.5 (7.2, 10.3) 9.6 (8.0, 11.5) <0.001
TG (mg/dL) 130.98 (92.04, 204.44) 82.30 (64.61, 99.34) 133.64 (109.74, 160.63) 255.77 (184.08, 389.84) <0.001
TC (mmol/L) 4.25 (3.54, 5.03) 3.83 (3.21, 4.47) 4.27 (3.64, 4.97) 4.70 (3.96, 5.54) <0.001
HDL-C (mmol/L) 1.11 (0.91, 1.40) 1.30 (1.07, 1.59) 1.12 (0.93, 1.37) 0.96 (0.77, 1.17) <0.001
LDL-C (mmol/L) 2.48 (1.85, 3.18) 2.21 (1.71, 2.79) 2.73 (2.07, 3.40) 2.56 (1.90, 3.37) <0.001
TyG Index 9.17 (8.73, 9.71) 8.52 (8.27, 8.73) 9.17 (9.02, 9.34) 10.00 (9.71, 10.50) <0.001
ALT (U/L) 19 (14, 29) 18 (13, 26) 20 (14, 29) 22 (15, 32) <0.001
ALB (g/L) 44 (40, 47) 44 (40, 47) 44 (40, 48) 44 (39, 47) 0.456
eGFR <60 mL/min/1.73 m2 162 (11.3) 36 (7.5) 68 (14.3) 58 (12.2) 0.004
Albuminuria, n (%) 504 (35.2) 130 (27.2) 171 (35.8) 203 (42.6) <0.001
Antidiabetic treatment
Diet alone, n (%) 134 (9.4) 22 (4.6) 47 (9.9) 65 (13.6) <0.001
Biguanides, n (%) 935 (65.3) 300 (62.8) 323 (67.7) 312 (65.4) 0.006
Sulfonylureas, n (%) 293 (20.5) 111 (23.2) 109 (22.9) 73 (15.3) 0.192
Thiazolidinediones, n (%) 26 (1.8) 10 (2.1) 5 (1.0) 11 (2.3) 0.18
α-glucosidase inhibitors, n (%) 395 (27.6) 143 (29.9) 135 (28.3) 117 (24.5) 0.771
Meglitinides, n (%) 195 (13.6) 63 (13.2) 70 (14.7) 62 (13) <0.001
SGLT-2 inhibitors, n (%) 28 (2.0) 0 (0) 1 (0.2) 27 (5.7) <0.001
GLP-1 receptor agonist, n (%) 44 (3.1) 4 (0.8) 6 (1.3) 34 (7.1) 0.08
DPP-IV inhibitor, n (%) 54 (3.8) 13 (2.7) 15 (3.1) 26 (5.4) <0.001
Biguanides, n (%) 935 (65.3) 300 (62.8) 323 (67.7) 312 (65.4) 0.006
Hypolipidemic treatment
Statins, n (%) 475 (33.2) 129 (27) 147 (30.8) 199 (41.7) <0.001
Fibrates, n (%) 32 (2.2) 11 (2.3) 6 (1.3) 15 (3.1) 0.06
Antihypertensive drugs, n (%) 578 (40.4) 192 (40.2) 188 (39.4) 198 (41.5) 0.8
RX with ACE-I/ARBs, n (%) 402 (28.1) 148 (31.0) 120 (25.2) 134 (28.1) 0.136

Notes: Quantitative variables are shown as median (interquartile range), and qualitative parameters are presented as numbers with the percentage in parentheses.

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WC, waist circumference; FPG, fasting plasma glucose; PBG, postprandial blood glucose; HbA1c, glycated hemoglobin; TG, total triglyceride; TC, total cholesterol; HDL-C, high density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; ALT, alanine aminotransferase; ALB, albumin; eGFR, estimated glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.